{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["ct.gov 1Q21"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"ct.gov 1Q21","index":0,"n_rows":156,"n_cols":9,"rows_kept":156,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title","Conditions ","Enrollment","Study Design","Dates"]
["Rare blood disorders","rilzarutinib","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia",194,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: September 2023\nStudy Completion: May 2025"]
["Rare blood disorders","rilzarutinib","\n• Phase 1\n• Phase 2\n","NCT03395210","A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia\n• Immune Thrombocytopenic Purpura",85,"\n\n• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2022\nStudy Completion: September 2023"]
["Rare blood disorders","Fitusiran (siRNA targeting Antithrombin/AT3)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B","• Hemophilia",12,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2024\nStudy Completion: December 2026"]
["Rare blood disorders","Fitusiran (siRNA targeting Antithrombin/AT3)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","• Hemophilia",244,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2026\nStudy Completion: October 2026"]
["Rare blood disorders","Fitusiran (siRNA targeting Antithrombin/AT3)  ","\nPhase 3\n","NCT03549871","A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","• Hemophilia",80,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2022\nStudy Completion: September 2022"]
["Rare blood disorders","Fitusiran (siRNA targeting Antithrombin/AT3)  ","\nPhase 3\n","NCT03417245","A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","• Hemophilia A\n• Hemophilia B",120,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 26, 2021\nStudy Completion: July 2021"]
["Rare blood disorders","Fitusiran (siRNA targeting Antithrombin/AT3)  ","\nPhase 3\n","NCT03417102","A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","• Hemophilia A\n• Hemophilia B",54,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 25, 2020\nStudy Completion: June 2021"]
["Rare blood disorders","Sutimlimab (BIVV009 - Anti Complement C1s mAb)","\nPhase 3\n","NCT03347422","A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion","• Cold Agglutinin Disease",40,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: December 2021\nStudy Completion: December 2021"]
["Rare blood disorders","Sutimlimab (BIVV009 - Anti Complement C1s mAb)","\nPhase 3\n","NCT03347396","A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)","• Agglutinin Disease, Cold",20,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2021\nStudy Completion: September 2021"]
["Rare blood disorders","Sutimlimab (BIVV009 - Anti Complement C1s mAb)","\nPhase 1\n","NCT03275454","A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)","• Purpura, Thrombocytopenic, Idiopathic",12,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 16, 2021\nStudy Completion: February 16, 2021"]
["Rare blood disorders","Fitusiran (siRNA targeting Antithrombin/AT3)  ","\n• Phase 1\n• Phase 2\n","NCT02554773","An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B","• Hemophilia A\n• Hemophilia B",37,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 2023\nStudy Completion: August 2023"]
["Rare blood disorders","Sutimlimab (BIVV009 - Anti Complement C1s mAb)","\nPhase 1\n","NCT02502903","Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","• Bullous Pemphigoid (BP)\n• Cold Agglutinin Disease (CAD)\n• Warm Autoimmune Hemolytic Anemia (WAIHA)\n• End-stage Renal Disease (ESRD)",122,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2021\nStudy Completion: March 31, 2021"]
["Rare blood disorders","BIVV020 (Complement C1S inhibitor)","\nPhase 1\n","NCT04802057","Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With BIVV020","• Autoimmune Haemolytic Anaemia",18,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2023\nStudy Completion: May 2023"]
["Rare blood disorders","BIVV001 (rFVIIIFc - vWF – XTEN)","\nPhase 1\n","NCT04770935","To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)","• Von Willebrand's Disease (VWD)",9,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Other","Primary Completion: August 2021\nStudy Completion: September 2021"]
["Rare blood disorders","BIVV001 (rFVIIIFc - vWF – XTEN)","\nPhase 3\n","NCT04759131","Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","• Hemophilia A",65,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 2023\nStudy Completion: February 2023"]
["Rare blood disorders","BIVV020 (Complement C1S inhibitor)","\nPhase 2\n","NCT04669600","A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia (ITP)",12,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2022\nStudy Completion: December 2023"]
["Rare blood disorders","BIVV020 (Complement C1S inhibitor)","\nPhase 1\n","NCT04269551","A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease","• Autoimmune Haemolytic Anaemia",18,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2022\nStudy Completion: October 2022"]
["Rare blood disorders","BIVV001 (rFVIIIFc - vWF – XTEN)","\nPhase 3\n","NCT04161495","A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand\nFactor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","• Factor VIII Deficiency",150,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2022\nStudy Completion: January 2022"]
["Rare blood disorders","BIVV003 (gene-editing technology)","\n• Phase 1\n• Phase 2\n","NCT03653247","A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease","• Sickle Cell Disease",8,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 2023\nStudy Completion: November 2023"]
["Rare blood disorders","ST400 (gene-editing technology)","\n• Phase 1\n• Phase 2\n","NCT03432364","A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)","• Transfusion Dependent Beta-thalassemia",6,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2021\nStudy Completion: March 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 2\n","NCT03793608","Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy","• Peanut Allergy",25,"\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 19, 2021\nStudy Completion: May 27, 2021"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT03782532","Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma","• Asthma",486,"\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: September 2022\nStudy Completion: September 2022"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 2\n","NCT03682770","Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)","• Peanut Allergy",149,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 16, 2020\nStudy Completion: October 6, 2021"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT03633617","Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","• Eosinophilic Esophagitis",321,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 16, 2021\nStudy Completion: July 12, 2022"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT03620747","Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","• Asthma",750,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2021\nStudy Completion: September 2021"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","• Asthma",354,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2023\nStudy Completion: October 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\n• Phase 2\n• Phase 3\n","NCT03346434","Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients #6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)","• Atopic Dermatitis",162,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 6, 2021\nStudy Completion: July 6, 2021"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT02948959","Evaluation of Dupilumab in Children With Uncontrolled Asthma","• Asthma",407,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: August 26, 2020\nStudy Completion: August 26, 2020"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants #6 Months to <18 Years of Age With Atopic Dermatitis (AD)","• Atopic Dermatitis",800,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 17, 2026\nStudy Completion: December 17, 2026"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT01949311","Open-label Study of Dupilumab in Patients With Atopic Dermatitis","• Atopic Dermatitis",2678,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 8, 2022\nStudy Completion: May 8, 2022"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",924,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2022\nStudy Completion: March 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","• Bullous Pemphigoid",98,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 27, 2023\nStudy Completion: September 15, 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04202679","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","• Neurodermatitis",150,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2021\nStudy Completion: December 2021"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04183335","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable","• Neurodermatitis",150,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 2021\nStudy Completion: April 2022"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab","• Chronic Spontaneous Urticaria",234,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 2022\nStudy Completion: April 2022"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT03930732","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",924,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 2022\nStudy Completion: September 2022"]
["I&I","SAR441236 (Tri-specific neutralizing mAb) ","\nPhase 1\n","NCT03705169","Pharmacokinetics of SAR441236","• HIV-1-infection",84,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: February 22, 2022\nStudy Completion: February 22, 2022"]
["I&I","sarilumab (anti-IL6 mAb) ","\nPhase 2\n","NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","• Juvenile Idiopathic Arthritis",72,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2023\nStudy Completion: April 2027"]
["I&I","sarilumab (anti-IL6 mAb) ","\nPhase 2\n","NCT02776735","An Open-label, Ascending, Repeated Dose- finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","• Juvenile Idiopathic Arthritis",100,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2021\nStudy Completion: November 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04442269","A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","• Allergic Bronchopulmonary Aspergillosis",170,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 7, 2023\nStudy Completion: October 23, 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04684524","Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)","• Allergic Fungal Rhinosinusitis",120,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2022\nStudy Completion: May 2023"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\nPhase 3\n","NCT04681729","Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","• Cold Urticaria",78,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 2022\nStudy Completion: October 2022"]
["I&I","Dupilumab (anti-IL4Rα mAb) ","\n• Phase 2\n• Phase 3\n","NCT04678856","Dupilumab in CRSsNP","• Chronic Rhinosinusitis Without Nasal Polyps\n• Sinusitis\n• Chronic Sinusitis\n• Sinus Disorder\n• Respiratory Disorder",240,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 2023\nStudy Completion: September 2023"]
["I&I","SAR441344","\nPhase 2\n","NCT04572841","Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)","• Sjögren's Syndrome",88,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2022\nStudy Completion: October 2022"]
["I&I","rilzarutinib","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients","• IgG4-Related Disease",25,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 2022\nStudy Completion: December 2022"]
["I&I","rilzarutinib","\nPhase 3\n","NCT03762265","A Study of PRN1008 in Patients With Pemphigus","• Pemphigus",131,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 2021\nStudy Completion: March 2023"]
["I&I","IRAK4 degrader","\nPhase 1\n","NCT04772885","A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)","• Healthy Volunteer\n• Atopic Dermatitis\n• Hidradenitis Suppurativa",124,"\n\n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 1, 2022\nStudy Completion: February 1, 2022"]
["I&I","itepekimab","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)","• Chronic Obstructive Pulmonary Disease",1170,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 2024\nStudy Completion: July 2024"]
["I&I","rilzarutinib","\nPhase 1\n","NCT04748926","Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants","• Healthy Volunteers",24,"\n\n• Allocation: Randomized\n• Intervention Model: Crossover Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Other","Primary Completion: May 2021\nStudy Completion: May 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 1\n","NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","• Multiple Myeloma",46,"\n\n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2023\nStudy Completion: November 2023"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 1\n","NCT03733717","Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","• Multiple Myeloma",25,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2020\nStudy Completion: September 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","• Multiple Myeloma",662,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2025\nStudy Completion: December 2025"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 3\n","NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","• Plasma Cell Myeloma",475,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2022\nStudy Completion: January 2025"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT02812706","Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients","• Multiple Myeloma",32,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 31, 2018\nStudy Completion: October 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 1\n","NCT02514668","A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","• Plasma Cell Myeloma",55,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2021\nStudy Completion: December 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 1\n","NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","• Plasma Cell Myeloma",76,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2023\nStudy Completion: January 2023"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 1\n","NCT02283775","SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients","• Plasma Cell Myeloma",89,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2021\nStudy Completion: March 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 1\n","NCT01749969","SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","• Plasma Cell Myeloma",60,"\n\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2021\nStudy Completion: December 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT01084252","Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","• Hematological Malignancy",351,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 21, 2018\nStudy Completion: July 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04294459","Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","• Immune System Disorder",42,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2022\nStudy Completion: March 2022"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 3\n","NCT04270409","Isatuximab in Combination With Lenalidomide and Dexamethasone in High- risk Smoldering Multiple Myeloma","• Plasma Cell Myeloma",300,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 2028\nStudy Completion: September 2033"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 2\n","NCT03860844","Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","• Acute Lymphoblastic Leukemia\n• Acute Myeloid Leukemia",96,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 2021\nStudy Completion: June 2022"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03769181","A Study of Isatuximab-based Therapy in Participants With Lymphoma","• Lymphoma",130,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2022\nStudy Completion: December 2022"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03637764","Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","• Neoplasm",350,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2022\nStudy Completion: May 2022"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03555149","A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","• Colorectal Cancer",382,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 30, 2023\nStudy Completion: October 30, 2023"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03367819","Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies","• Prostate Cancer\n• Non-small Cell Lung Cancer",134,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2021\nStudy Completion: March 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 3\n","NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",302,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 1, 2020\nStudy Completion: December 2022"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 1\n","NCT03233139","Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies","• Advanced Malignancies",81,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 1, 2023\nStudy Completion: August 1, 2023"]
["Oncology","Isatuximab (anti-CD38 mAb)","\nPhase 3\n","NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",307,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 22, 2018\nStudy Completion: March 2022"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 2\n","NCT04154943","Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma","• Cutaneous Squamous Cell Carcinoma",76,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 22, 2021\nStudy Completion: December 23, 2024"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 3\n","NCT03969004","Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","• Cutaneous Squamous Cell Carcinoma",75,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 16, 2023\nStudy Completion: February 11, 2026"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 1\n","NCT03889912","Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma","• Cutaneous Squamous Cell Carcinoma",17,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 23, 2022\nStudy Completion: February 23, 2022"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03690869","REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma","• Relapsed Solid Tumor\n• Refractory Solid Tumor\n• Relapsed Central Nervous System Tumor\n• Refractory Central Nervous System Tumor\n• Diffuse Intrinsic Pontine Glioma\n• High Grade Glioma",130,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 28, 2025\nStudy Completion: January 28, 2025"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 3\n","NCT03515629","REGN2810 (Anti-PD-1 Antibody), Platinum- based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer","• Non-small Cell Lung Cancer",5,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 2, 2021\nStudy Completion: August 2, 2021"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 3\n","NCT03409614","Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","• Non-small Cell Lung Cancer",790,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 1, 2023\nStudy Completion: May 1, 2023"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 1\n","NCT03198130","An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)","• Recurrent Squamous Cell Carcinoma of Head\n• Recurrent Squamous Cell Carcinoma of Neck\n• Metastatic Squamous Cell Carcinoma of Head\n• Metastatic Squamous Cell Carcinoma Neck",33,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 27, 2019\nStudy Completion: February 21, 2020"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 2\n","NCT03132636","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy","• Carcinoma, Basal Cell",137,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 14, 2021\nStudy Completion: May 9, 2022"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 3\n","NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","• Carcinoma#Non-Small-Cell Lung\n• Lung Carcinomas, Non- Small-Cell\n• Non-small-cell Lung Carcinoma\n• Nonsmall Cell Lung Cancer",712,"\n\n• Allocation: Randomized\n• Intervention Model: Crossover Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 1, 2022\nStudy Completion: November 1, 2022"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 2\n","NCT02760498","Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma","• Advanced Cutaneous Squamous Cell Carcinoma",433,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 20, 2025\nStudy Completion: December 1, 2025"]
["Oncology","tusamitamab ravtansine","\nPhase 2\n","NCT04524689","SAR408701 in Combination With Pembrolizumab and Pembrolizumab Alone in Patients With Non-squamous Non-small Cell Lung Cancer (NSQ NSCLC)","• Non-squamous Non-small- cell Lung Cancer (NSQ NSCLC)",99,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 2022\nStudy Completion: April 2023"]
["Oncology","tusamitamab ravtansine","\nPhase 2\n","NCT04394624","SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)","• Non-small Cell Lung Cancer Metastatic",36,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2021\nStudy Completion: February 2022"]
["Oncology","tusamitamab ravtansine","\nPhase 3\n","NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non- small Cell Lung Cancer Patients","• Non-small Cell Lung Cancer Metastatic",554,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2024\nStudy Completion: March 2024"]
["Oncology","amcenestrant","\nPhase 1\n","NCT03816839","Evaluation of Orally Administered SAR439859 in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)","• Breast Cancer",12,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 27, 2020\nStudy Completion: July 2021"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 2\n","NCT03430063","A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer","• Advanced Non-Small Cell Lung Carcinoma",28,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 18, 2021\nStudy Completion: August 18, 2021"]
["Oncology","tusamitamab ravtansine","\nPhase 1\n","NCT03324113","Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","• Neoplasm Malignant",63,"\n\n• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2022\nStudy Completion: September 2022"]
["Oncology","amcenestrant","\n• Phase 1\n• Phase 2\n","NCT03284957","Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Other\nAnti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","• Breast Cancer",305,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2023\nStudy Completion: March 2023"]
["Oncology","Cemiplimab (PD-1 inhibitor)","\nPhase 3\n","NCT03257267","Study of Cemiplimab in Adults With Cervical Cancer","• Squamous Cell Carcinoma (SCC)\n• Recurrent or Metastatic, Platinum-refractory Cervical Cancer",590,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 31, 2021\nStudy Completion: July 7, 2023"]
["Oncology","SAR439459 (TGFß inhibitor mAb)","\nPhase 1\n","NCT03192345","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors","• Malignant Solid Tumor",350,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 2022\nStudy Completion: September 2022"]
["Oncology","tusamitamab ravtansine","\n• Phase 1\n• Phase 2\n","NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors","• Neoplasm Malignant",313,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2021\nStudy Completion: September 2021"]
["Oncology","amcenestrant","\nPhase 3\n","NCT04478266","Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer","• Breast Cancer",1066,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 2024\nStudy Completion: August 2027"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT04418661","Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies","• Metastatic Neoplasm",24,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2023\nStudy Completion: May 2023"]
["Oncology","amcenestrant","\nPhase 2\n","NCT04191382","Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post- menopausal Patients With ER+, HER2- Pre- operative Post-menopausal Primary Breast Cancer (AMEERA-4)","• Breast Cancer",126,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 2021\nStudy Completion: August 2021"]
["Oncology","amcenestrant","\nPhase 2\n","NCT04059484","Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","• Breast Cancer Metastatic",372,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 2021\nStudy Completion: July 2025"]
["Oncology","SAR444245 - THOR 707","\n• Phase 1\n• Phase 2\n","NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors","• Solid Tumor, Unspecified, Adult",300,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 2022\nStudy Completion: June 2022"]
["Oncology","SAR442085 (Anti CD38 mAb Fc engineered)","\nPhase 1\n","NCT04000282","First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma","• Plasma Cell Myeloma",78,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2023\nStudy Completion: May 2023"]
["Oncology","SAR442720 (SHP2 inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03989115","Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC","• Solid Tumor",168,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2022\nStudy Completion: April 30, 2022"]
["Oncology","SAR441000 cytokine mRNA","\nPhase 1\n","NCT03871348","A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","• Metastatic Neoplasm",231,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2023\nStudy Completion: February 2024"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT03634982","Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","• Solid Tumors",210,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 1, 2021\nStudy Completion: October 1, 2021"]
["Oncology","Isatuximab (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM","• Plasma Cell Myeloma Refractory",66,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2024\nStudy Completion: December 2025"]
["Oncology","SAR442257 (anti CD38xCD28xCD3 trispecific mAb)","\nPhase 1\n","NCT04401020","First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","• Neoplasm Malignant",57,"\n\n• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 2024\nStudy Completion: March 2024"]
["Rare disease","Venglustat (GCS inhibitor) ","\nPhase 3\n","NCT04221451","A Multinational, Randomized, Double- blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics,\nPharmacokinetics, and Safety of Venglustat in Late-onset GM2","• Tay-Sachs Disease Sandhoff Disease",62,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 2023\nStudy Completion: November 2023"]
["Rare disease","Venglustat (GCS inhibitor) ","\n• Phase 2\n• Phase 3\n","NCT03523728","A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients","• Polycystic Kidney, Autosomal Dominant",640,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 2023\nStudy Completion: November 2023"]
["Rare disease","Eliglustat","\nPhase 3\n","NCT03485677","Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3","• Gaucher's Disease Type I\n• Gaucher's Disease Type III",60,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 2022\nStudy Completion: November 2025"]
["Rare disease","GZ402666 (avalglucosidase alfa) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","• Glycogen Storage Disease Type II-Pompe's Disease",22,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2019\nStudy Completion: December 2024"]
["Rare disease","Venglustat (GCS inhibitor) ","\n• Phase 2\n• Phase 3\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3","• Gaucher Disease Type 1- Gaucher Disease Type 3",49,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2022\nStudy Completion: December 2022"]
["Rare disease","GZ402666 (avalglucosidase alfa) ","\nPhase 3\n","NCT02782741","Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","• Glycogen Storage Disease Type II;Pompe's Disease",100,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 19, 2020\nStudy Completion: September 2024"]
["Rare disease","Eliglustat","\nPhase 3\n","NCT02536755","Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease","• Gaucher's Disease",32,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 1, 2020\nStudy Completion: June 22, 2021"]
["Rare disease","GZ402666 (avalglucosidase alfa) ","\n• Phase 2\n• Phase 3\n","NCT02032524","Avalglucosidase Alfa Extension Study","• Glycogen Storage Disease Type II Pompe Disease",21,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2021\nStudy Completion: December 2021"]
["Rare disease","GZ402665 (olipudase alfa) ","\nPhase 2\n","NCT02004704","A Long-Term Study of Olipudase Alfa\nin Patients With Acid Sphingomyelinase Deficiency","• Sphingomyelin Lipidosis",25,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 2023\nStudy Completion: September 2023"]
["Rare disease","GZ402665 (olipudase alfa) ","\n• Phase 2\n• Phase 3\n","NCT02004691","Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency","• Sphingomyelin Lipidosis",36,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 17, 2019\nStudy Completion: October 2023"]
["Rare disease","Venglustat (GCS inhibitor) ","\nPhase 3\n","NCT04705051","Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat","• Congenital Cystic Kidney Disease",640,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 2025\nStudy Completion: November 2025"]
["Rare disease","SAR339375 (Anti-miR21 RNA) ","\nPhase 2\n","NCT02855268","Study of Lademirsen (SAR339375) in Patients With Alport Syndrome","• Alport's Syndrome",45,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: June 2023\nStudy Completion: June 2023"]
["MS & Neuro","tolebrutinub","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Primary Progressive Multiple Sclerosis",990,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["MS & Neuro","tolebrutinub","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Secondary Progressive Multiple Sclerosis",1290,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["MS & Neuro","tolebrutinub","\nPhase 3\n","NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2023\nStudy Completion: August 2023"]
["MS & Neuro","tolebrutinub","\nPhase 3\n","NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2023\nStudy Completion: August 2023"]
["MS & Neuro","tolebrutinub","\nPhase 1\n","NCT04171310","Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects","• Multiple Sclerosis",6,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 30, 2019\nStudy Completion: December 30, 2019"]
["MS & Neuro","tolebrutinub","\nPhase 2\n","NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis","• Relapsing Multiple Sclerosis",126,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2025\nStudy Completion: April 2025"]
["MS & Neuro","Teriflunomide","\nPhase 3\n","NCT02201108","Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis","• Multiple Sclerosis",166,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 25, 2019\nStudy Completion: September 29, 2021"]
["Vaccines","Meninge Vaccine, North America","\nPhase 3\n","NCT04084769","Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone\nor Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","• Meningococcal Infection (Healthy Volunteers)",572,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: September 14, 2020\nStudy Completion: September 14, 2020"]
["Vaccines","New Pertussis Vaccine, North America","\nPhase 1\n","NCT03958799","A Study to Describe the Safety Profile and Compare the Immune Response of 4\nDifferent Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada","• Tetanus Immunisation (Healthy Volunteers)\n• Diphtheria Immunisation (Healthy Volunteers)\n• Pertussis Immunisation (Healthy Volunteers)",100,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: May 2021\nStudy Completion: May 2021"]
["Vaccines","Meninge Vaccine, Greater Europe","\nPhase 3\n","NCT03890367","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in Europeans Toddlers","• Meningococcal Infection (Healthy Volunteers)",709,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 14, 2020\nStudy Completion: October 14, 2020"]
["Vaccines","Meninge Vaccine\nAfrica, Middle-East","\nPhase 3\n","NCT03869866","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","• Healthy Volunteers (Meningococcal Infection)",330,"\n\n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: November 2021\nStudy Completion: November 2021"]
["Vaccines","Meninge Vaccine\nLatin America, North America","\nPhase 3\n","NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","• Healthy Volunteers (Meningococcal Infection)",1070,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 2023\nStudy Completion: March 2023"]
["Vaccines","Meninge Vaccine, Asia Pacific, Greater Europe, Latin America","\nPhase 3\n","NCT03630705","Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","• Healthy Volunteers (Meningococcal Infection)",525,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: January 2022\nStudy Completion: January 2022"]
["Vaccines","Meninge Vaccine, Greater Europe","\nPhase 3\n","NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","• Meningococcal Infections",1540,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 2023\nStudy Completion: August 2023"]
["Vaccines","Meninge Vaccine, North America","\nPhase 3\n","NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","• Meningococcal Infections",2475,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: December 2022\nStudy Completion: December 2022"]
["Vaccines","Dengue Vaccine, Asia Pacific, Latin America ","Epi\n","NCT02948933","Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine","• Dengue Fever\n• Dengue Hemorrhagic Fever",30000,"\n\n• Observational Model: Cohort\n• Time Perspective: Prospective","Primary Completion: October 18, 2024\nStudy Completion: October 18, 2024"]
["Vaccines","AcP Primary Vaccine, North America","Phase 4\n","NCT00855855","Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease","• Haemophilus Infections\n• Diphtheria\n• Tetanus\n• Polio\n• Pertussis",20830,"\n\n• Observational Model: Cohort\n• Time Perspective: Cross-Sectional","Primary Completion: December 2014\nStudy Completion: December 2014"]
["Vaccines","Next Gen Flu, North America","\nPhase 1\n","NCT04451954","Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","• Influenza",210,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 2021\nStudy Completion: September 2021"]
["Vaccines","Meninge Vaccine, Asia Pacific","\nPhase 3\n","NCT04368429","Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","• Meningococcal Infection (Healthy Volunteers)",360,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: November 7, 2020\nStudy Completion: November 7, 2020"]
["Vaccines","Flu QIV SHZ – CN, Asia Pacific","\nPhase 3\n","NCT04210349","Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","• Influenza",7106,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: December 2, 2020\nStudy Completion: December 2, 2020"]
["Vaccines","Next Gen Flu, North America","\nPhase 1\n","NCT04144179","Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age","• Influenza",150,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 24, 2020\nStudy Completion: February 24, 2020"]
["Vaccines","Meninge Vaccine\nAfrica, Middle East","\nPhase 3\n","NCT04143061","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa","• Healthy Volunteers (Meningococcal Infection)",1332,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: February 2022\nStudy Completion: February 2022"]
["Vaccines","Meninge Vaccine, North America","\nPhase 3\n","NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","• Meningococcal Infection (Healthy Volunteers)",471,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: April 1, 2020\nStudy Completion: April 2022"]
["Vaccines","Flu QIV HD Vaccine, Greater Europe","\nPhase 3\n","NCT04137887","Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","• Influenza (Healthy Volunteers)",121000,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 2023\nStudy Completion: September 2023"]
["Vaccines","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen in Pediatric and Adult Populations and as Single Booster Dose to a Subset of Adults","• Rabies (Healthy Volunteers)",1010,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 2021\nStudy Completion: August 2021"]
["Vaccines","Rabies Vaccine, Greater Europe","\nPhase 3\n","NCT03965962","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","• Rabies (Healthy Volunteers)",640,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 27, 2020\nStudy Completion: June 2021"]
["Vaccines","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT03700242","Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year","• Healthy Volunteers (Rabies Immunization)",570,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: January 19, 2019\nStudy Completion: April 8, 2020"]
["Vaccines","Flu seasonal Vaccine, Asia Pacific","\nPhase 3\n","NCT04537234","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD)\nCompared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","• Influenza (Healthy Volunteers)",165,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: February 9, 2021\nStudy Completion: February 9, 2021"]
["Vaccines","COVID-19, North America","\n• Phase 1\n• Phase 2\n","NCT04537208","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","• COVID-19 (Healthy Volunteers)",440,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: November 2021\nStudy Completion: November 2021"]
["Vaccines","Flu QIV HD Vaccine, Asia Pacific","\nPhase 3\n","NCT04498832","Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD)\nCompared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","• Influenza (Healthy Volunteers)",2100,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 14, 2021\nStudy Completion: January 14, 2021"]
["Vaccines","RSV Infant, Latin America","\n• Phase 1\n• Phase 2\n","NCT04491877","Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","• Respiratory Syncytial Virus Infection",300,"\n\n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 2023\nStudy Completion: April 2023"]
["Vaccines","Meninge Vaccine, Asia Pacific, Greater Europe","\nPhase 3\n","NCT04490018","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","• Meningococcal Infection (Healthy Volunteers)",464,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 2021\nStudy Completion: December 2021"]
["Vaccines","Shanta Fully Liquid Hexavalent Vaccine, Asia Pacific","\nPhase 3\n","NCT04429295","Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","• Pertussis Immunisation\n• Diphtheria Immunisation\n• Polio Immunisation\n• Hepatitis B Immunisation\n• Haemophilus Influenzae Type B Immunisation\n• Tetanus Immunisation\n• Rotavirus Immunisation\n• Pneumococcal Immunisation",460,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: February 27, 2021\nStudy Completion: November 2021"]
["Vaccines","Skypac, North America","\nPhase 2\n","NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","• Pneumococcal Immunisation\n• Diphtheria Immunisation\n• Tetanus Immunisation\n• Pertussis Immunisation\n• Hepatitis B Immunisation\n• Haemophilus Influenzae Type b Immunisation\n• Polio Immunisation\n• Measles Immunisation\n• Rubella Immunisation\n• Varicella Immunisation\n• Mumps Immunisation",840,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 2023\nStudy Completion: April 2023"]
["Vaccines","Adacel Quadra Vaccine, Africa, Middle East","\nPhase 4\n","NCT04300192","Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","• Pertussis Immunisation\n• Diphtheria Immunisation\n• Tetanus Immunisation\n• Polyomyelitis Vaccine",350,"\n\n• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: April 2022\nStudy Completion: April 2022"]
["Vaccines","HSV Vaccine, North America","\n• Phase 1\n• Phase 2\n","NCT04222985","Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2","• Genital Herpes",381,"\n\n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 2021\nStudy Completion: May 2021"]
["Vaccines","vYF Vaccine, North America","\n• Phase 1\n• Phase 2\n","NCT04142086","Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults","• Yellow Fever (Healthy Volunteers)",572,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: June 2021\nStudy Completion: June 2021"]
["Vaccines","Meninge B, \nLatin America, Greater Europe, North America","\n• Phase 1\n• Phase 2\n","NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","• Meningococcal Immunisation",1800,"\n\n• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 2025\nStudy Completion: March 2025"]
["Vaccines","COVID-19 mRNA, \nLatin America,North America","\n• Phase 1\n• Phase 2\n","NCT04798027","Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older","• COVID-19",415,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: May 2022\nStudy Completion: May 2022"]
["Vaccines","COVID-19,\nLatin America,North America","\nPhase 2\n","NCT04762680","Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older","• COVID-19 (Healthy Volunteers)",722,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 2022\nStudy Completion: April 2022"]
["Vaccines","Rabies Vaccine\nAsia Pacific","\nPhase 3\n","NCT04594551","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adults in Thaïland","• Rabies (Healthy Volunteers)",201,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 2021\nStudy Completion: June 2021"]
["Vaccines","Skypac\nNorth America","\nPhase 2\n","NCT04583618","Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","• Pneumoccocal Immunisation",750,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 2021\nStudy Completion: October 2021"]
["Vaccines","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT04478084","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","• Rabies (Healthy Volunteers)",336,"\n\n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: January 2022\nStudy Completion: April 2022"]